Clearside Biomedical Reports First Quarter 2025 Financial Results and Provides Corporate Update
Published on May 15, 2025
ALPHARETTA, Ga.—Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company developing therapies for the back of the eye through the suprachoroidal space (SCS), has announced its financial results for the first quarter ending March 31, 2025, and provided a corporate update. License and other revenue for the first quarter of 2025 was $2.3 million, the company stated, compared with $0.2 million for the first quarter of 2024. The increase was primarily attributable to license fees from partners in the first quarter of 2025, the company said. Research and development (R&D) expenses for the first quarter of 2025 were reported at $4.5 million, compared with $5.6 million for the first quarter of 2024, a decrease the company attributed primarily to lower clinical trial costs following completion of the ODYSSEY phase 2b trial. General and administrative expenses remained constant at $2.8 million in the first quarters of 2025 and 2024.